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285* Inﬂuence of inhaled hypertonic saline combined with airway
clearance on SpO2, heart rate, dyspnoea and wet sputum weight
in hospitalised CF patients
S. Vanlaethem1, F. Van Ginderdeuren1, H. Eyns1, A. Malfroot1. 1CF Clinic, UZ
Brussel, Brussels, Belgium
Background: Short- and longer term studies have shown that inhalation of hy-
pertonic saline (HS) is well tolerated, improves lung function, quality of life and
reduces exacerbations in CF patients. We are interested in the effect of inhaling
hypertonic saline (NaCl 6%) during airway clearance (AC), using two different
inhalation devices.
Methods: In this randomised cross-over study 15 CF patients were included.
Patients performed AC combined with inhalation of HS, using the Pari Turbo Boy
N compressor with LC Sprint nebuliser (PLC) on day 1, the E-Flow Rapid (EF) on
day 2 and no inhalation therapy on day 3. All patients had treatment sessions of 30
minutes by an experienced physiotherapist.
Results: No signiﬁcant difference in SpO2, heart rate and Borg score before and
after each treatment in the 3 consecutive days was found, but patients evacuated
signiﬁcantly more sputum (P< 0.005), combining inhalation of HS with AC on day
1 and 2 for both nebulisers. Mean nebulisation time was signiﬁcantly longer for
the compressor compared to the E-Flow Rapid.
Conclusion: Inhaling HS during AC evacuates more sputum and causes no side
effects. A well-considered choice of the inhalation device can reduce the inhalation
time signiﬁcantly.
286* Use and perceived beneﬁts of nebulised hypertonic saline (HS)
treatment in adult patients with cystic ﬁbrosis
H.B. Langman1, V.J. Gettins1, J. Redfern1, R.J. Bright-Thomas1, A.M. Jones1,
A.K. Webb1, M.E. Dodd1. 1Adult Cystic Fibrosis Unit, Wythenshawe Hospital,
Manchester, United Kingdom
Background: Beneﬁts of nebulised HS are well recognised (1). We have introduced
this treatment into our routine care but were initially concerned about bronchocon-
striction and commenced some patients on 3.9% HS.
Aim: To investigate usage of HS and patient’s perception of beneﬁts.
Methods: Notes of patients who received a test dose of HS were examined for
gender, age, FEV1% predicted, HS tonicity, delivery device, bronchodilator use
and subsequent prescription. Patients were invited to answer a short questionnaire
relating to perceived beneﬁts, HS and rhDNase usage.
Results: 73 patients (37 male) received a total of 86 test doses, mean(SD) age
29(8.9) years, FEV1%pred 46.6(2.3)%. 44/73 (60%) received prescription for 7%
(13/44 started on 3.9% and progressed to 7%), 24/73 (33%) were prescribed 3.9%
and HS was not prescribed for 5 (7%) patients. A variety of nebuliser systems
were used. A bronchodilator was used pre HS for 53/73, mixed with HS 18/73
and not used in 2/73. 47/73 (64%) patients completed a questionnaire. 15/47 used
HS od, 1/47 bd, 5/47 on alternate days, 10/47 only when unwell and 16/47 only
in hospital. 25/47 (53%) also inhaled rhDNase. 33/47 (70%) found it easy to ﬁt
into their treatment regimen. 39/47 (69%) found their sputum easier to move after
nebulised HS and 31/47 (66%) felt their airway clearance treatment was easier.
There was no signiﬁcant difference in perceived sputum clearance between those
using 7%HS (n = 31) and 3.9%HS (n = 16).
Conclusion: HS (both 7% and 3.9%) is well tolerated by adult patients with mild
to severe CF lung disease. Patients report HS is a useful adjunct to their airway
clearance treatment that is easy to ﬁt into their treatment regimen.
Reference(s)
[1] Elkins et al. NEJM 2006;354:3.
287 Audit of a physiotherapy led nebuliser concordance programme
for cystic ﬁbrosis adults
L. Gumery1, S. Cameron1, A. Kailey1, J. Lee1, J. Whitehouse1. 1West Midlands
Regional CF Centre, Heart of England NHS Foundation Trust, Birmingham,
United Kingdom
Background: Concordance with nebulised drug therapy (NDT) was recognised as
suboptimal.
Aim: To optimise NDT and assess the beneﬁt of a physiotherapy led nebuliser
concordance programme (NCP) via audit.
Method: CF adults who commenced new NDT from June 2006 were
assessed/educated at initial dose/1/6/12mths re: potential beneﬁts/side ef-
fects/contraindications; timing/order in relation to other drugs/ACT and nebuliser
care. Drugs commenced included Pulmozyme, Colomycin, TOBI and Hypertonic
saline. The physiotherapist completed a NCP document; data collected included
demographics, lung function, and assessment of knowledge, concordance and
nebuliser technology.
Results: CF adults (16−62 yrs, M 61%: F 39%) entered the NCP, 42 discontinued
new NDT and 70 await ﬁnal review. Data is presented for 120 CF adults who
completed NCP to date. Lung disease severity was mild in 53%, moderate 36%
and severe 11%. Post-NCP lung function improved in 58% and remained the same
in 4%. Knowledge of NDT beneﬁts improved in 65% and remained the same in
30%. Knowledge of side effects/contraindications improved in 49% and in 48%
remained the same. Post-NCP 98% were aware of dosage/storage of NDT and 97%
reported full concordance. Timing/order of drugs was correct in 86% and 90%
respectively. Post-NCP nebuliser hygiene/maintenance were optimal in 86%.
Conclusion: The NCP in conjunction with the provision of new, more efﬁcient,
faster nebuliser technology appears to have enhanced knowledge and reported
concordance with NDT and improved outcome in CF adults.
Recommendations: Currently being undertaken are 12 month follow-up, dissemi-
nation of results and development of a patient information leaﬂet, available via the
internet, to support the NCP programme.
288* Attitudes to recreational androgenic anabolic steroids among
adult CF patients
A. Morris1, H. Miller1, M.J. Ledson1, M.J. Walshaw1. 1Regional Adult CF Unit,
The Cardiothoracic Centre, Liverpool, United Kingdom
Introduction: The use of androgenic anabolic steroids (AAS) is becoming more
popular in recreational gyms, and CF patients using such facilities may be exposed
to these unapproved substances. To look at this further, we surveyed patients at our
adult CF unit who were regular gym users about their attitudes to AAS.
Method: Although we identiﬁed a number of CF patients who might be using AAS,
only 4 (mean age 21 years, range 18−25, all male) were willing to be interviewed.
Using a structured questionnaire, we asked what steroids they used, their reasons
for doing so, their expectations and experiences, and any complications.
Results: In all cases, patients were introduced to AAS by other gym users and took
nandralone, sustanon, and methandrostenolone in varying doses for between 6 and
12 weeks. Patients expected to put on weight, gain muscle, and be capable of more
exercise; 2 indicated that improving body image was also a factor. The desire to
be seen as ‘normal’ by peers was a common theme. In practice, all gained some
muscle mass, and 3 had improved pulmonary function: in 1, hospital admission was
unnecessary for 7 months. Whilst all indicated they had more self conﬁdence whilst
taking AAS as a result of improved body mass, 3 noticed increased aggression and
1 acne. Only 1 was worried about possible heart side effects: all indicated they may
use AAS again. No patient considered informing the CF team ﬁrst due to possible
disapproval.
Conclusions: Young male CF adults can be sensitive about body image, and
those exercising in gyms may be encouraged to use illegal anabolic steroids. CF
care teams need to be aware of this, in order to work with these individuals to
minimise the physiological and psychological complications that may occur in these
vulnerable young adults.
